Cancer cells divide and multiply rapidly within the ovarian cancer tumor. These cancer cells carry special types of electrically charged elements that play a role during the cell division process. Other healthy cells in the same anatomical region multiply at a much slower rate, if at all, and/or have other different properties such as a different size, compared to the cancer cells. Thus, normal cells rarely include the same electric properties as the dividing cancer cells and are not expected to be affected by TTFields.
TTFields Mechanism of Action
The NovoTTF-100L(O) device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the skin and other superficial tissues. These fields are known as Tumor Treating Fields or TTFields. Due to the unique shape of cancer cells when they are multiplying, TTFields have been shown to cause certain building blocks of these cells to pile up in such a way that destroys the entire dividing cell. In addition, cancer cells also contain miniature building blocks that move essential parts of the cells from place to place during division. TTFields have been shown to cause these building blocks to fail to function normally since they have a special type of electric charge. As a result of these two effects, preliminary study data indicate that cancer tumor growth is inhibited after continuous exposure to TTFields. Preclinical data also indicate that TTFields affect the healthy tissues within the abdominal/pelvis region much less than the cancer cells, if at all.
A summary of TTFields’ mechanism of action is illustrated in the following animation:
TTFIELDS ARE NOT APPROVED FOR THE TREATMENT OF OVARIAN CANCER. THE SAFETY AND EFFECTIVENESS OF TTFIELDS FOR OVARIAN CANCER HAS NOT BEEN ESTABLISHED.
Past preclinical experience
TTFields were found to have an inhibitory effect on the growth rate of ovarian cancer cells grown in the lab. In a series of experiments, dividing ovarian cancer cells were shown to have severe structural abnormalities under TTFields, leading to their death, while control ovarian cells grown under the same conditions proliferated. Ovarian cancer cells treated with TTFields in combination with standard chemotherapy used for the treatment of patients suffering from this condition, have demonstrated an even greater anti-tumor effect. The effect of combining paclitaxel to TTFields in treating ovarian cancer cells in the lab suggested a synergistic effect, meaning a greater inhibitory effect on cells’ proliferation than the combination of each of the treatments administered separately. These are some of the preclinical results demonstrating the potential of TTFields to affect ovarian cancer cells’ growth. Preclinical data do not always translate into similar effect in real patients. Therefore, the safety and preliminary efficacy of TTFields must be verified in clinical trials.
Past clinical experience
A number of systems developed to deliver TTFields to different tumors have been tested to date. The main difference between the previously tested systems and the NovoTTF-100L(O) is the frequency of TTFields provided by each system and the anatomical region they were applied to. The frequency is adjusted by the manufacturer of the systems in order to optimize the treatment for each treated cancer, based on data from laboratory experiments.The NovoTTF-100A System is approved by the FDA for the treatment of newly diagnosed and recurrent GBM and the same system has a CE Mark in Europe for the treatment of GBM, while the NovoTTF-100L has a CE Mark in Europe for the treatment of non-small-cell lung cancer.
Based on the science behind TTFields and the clinical results to date, the NovoTTF-100L(O) System is not expected to have systemic side effects in patients suffering from ovarian carcinoma. In previous studies performed with the NovoTTF-100 Systems, many patients have experienced local skin irritation beneath the transducer arrays.In a previous clinical trial for non-small-cell lung cancer, the following adverse events were reported:
The information provided in this website is partial, and you should consult with your treating physician concerning the complete safety profile of TTFields.
Please note that while the adverse event information from previous clinical trials may be relevant for the use of the device for ovarian cancer, it is not specific to this condition. The safety profile of TTFields in ovarian cancer has not been established and may be different.